Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide (TP53-EphA-2-CAR-DC) in combination with ICIs. It aims to: assess the safety and antitumor effects of TP53-EphA-2-CAR-DC vaccine; detect T cell response against TP53 mutant peptide and tumor neoepitopes after the treatment with TP53-EphA-2-CAR-DC vaccine and ICIs.

Trial Details

NCT ID
NCT05631886
Phase
PHASE1
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • TP53-EphA-2-CAR-DC
  • Abraxane
  • Cyclophosphamide
  • anti-PD-1 antibody
  • Anti-CTLA4 Monoclonal Antibody
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age 18-75 (inclusive).
  • ECOG performance status ≤2 and Estimated life expectancy of more than 3 months.
  • Local advanced/metastatic solid tumors or R/R lymphomas confirmed by histopathology or cytology with documentation of tumor EphA2 positive (≥20%) a…
  • No clinical response to standard frontline therapy or no standard therapy exists for solid tumors. Relapse after treatment with ≥2 lines systemic t…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →